Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31042359 | 1.00 | APLNR (0.42) | APLNRCYP1A2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL31073192 | 1.00 | APLNR (0.42) | APLNRCYP1A2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL7365019 | 0.82 | APLNR (0.46) | APLNRCYP1A2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL21556841 | 0.81 | APLNR (0.31) | APLNR | |
| SCHEMBL26125642 | 0.81 | NPC1 (0.33) | APLNRALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL26125646 | 0.81 | NPC1 (0.33) | APLNRALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL3049989 | 0.81 | APLNR (0.39) | APLNRCYP1A2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL9185287 | 0.81 | ADRA2B (0.38) | ALDH1A1CYP2D6 | |
| SCHEMBL24010070 | 0.80 | APLNR (0.41) | APLNRALDH1A1 | |
| SCHEMBL6160560 | 0.80 | APLNR (0.41) | APLNRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| CN-115448882-A | Benzoheterocyclic compounds useful for the treatment of EP2, EP4 receptor mediated diseases | 武汉人福创新药物研发中心有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-11225601-B2 | Photo-crosslinkable emissive molecular materials | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| CN-111909083-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-106660982-B | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-09-08 | — | — | CN | disclosed |
| WO-2011089416-A1 | PYRAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | WO | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| WO-2010086820-A1 | 4-AMINO-5-OXO-7, 8-DIHYDROPYRIMIDO [5,4-F] [1,4] OXAZEPIN-6 (5H) -YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PFIZER INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5624948-A | TREATMENT OF BRONCHIAL ASTHMA | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-29 | — | — | US | disclosed |
| EP-0699668-A1 | 1-(2-BENZIMIDAZOLYL)-1,5-DIAZACYCLOOCTANE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 1996-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | APLNR 1157/4885CYP1A2 917/4885ALDH1A1 158/4885 |
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | APLNR 3292/4885CYP1A2 2772/4885ALDH1A1 3599/4885 |
| US-11225601-B2 | Photo-crosslinkable emissive molecular materials | TYR, PNMT, INMT | APLNR 2267/4885CYP1A2 1416/4885ALDH1A1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.